The initial proposed clinical study will be conducted in adult head and neck cancer
subjects. This will be an open-labeled, proof of concept trial to evaluate the efficacy,
safety and tolerability of EISO in a form of oral rinse as adjunctive therapy to standard of
care. Santalis believes that the proposed study is a prudent and appropriate approach to
investigate the potential of their product to prevent or improve oral mucositis symptoms
commonly seen in subjects undergoing radiotherapy with or without chemotherapy.
The objectives of this proof of concept trial are: to evaluate the efficacy, safety and
tolerability of SAN005 when administered to adults for the prevention and treatment of
radiation induced oral mucositis.
Subjects will be instructed on the administration of study medication thrice daily till oral
mucositis resolves. Subjects will return to the clinic once a week while receiving radiation
and then once every two weeks once their radiation has been completed and then until their
mucositis has resolved for the Final Study Visit.
Preliminary Efficacy Evaluation will be the severity of pain rated by the NRPS and mucositis
grade by RTOG criteria at Visit 7 (Day 36). Additional secondary efficacy evaluations will
include the severity of pain rated by the NRPS and mucositis grade by RTOG criteria at each
study visit, frequency of the PEG tube for feeding during the duration of treatment and
weight loss from baseline through Visit 5 and 7. The time of mucositis onset and duration
will also be used in assessing efficacy. Additional secondary and exploratory endpoints will
be outlined in the statistical analysis plan. The overall efficacy is determined by
comparing the data to historical controls. Safety will be assessed by evaluating adverse
events (AEs) with respect to severity, duration, and relationship to study drug. In addition
tolerability evaluations will be performed at each study visit.
1. Subjects with head and neck cancer involving the oropharynx or oral cavity, who are
expected to undergo high dose radiation therapy (i.e., ≥ 60 Gy) that typically
results in oral mucositis, with or without concurrent chemotherapy or biologic
2. At least 18 years of age
3. Estimated survival of at least 6 months.
4. No prior radiation therapy to the head and neck area, and no chemotherapy within the
last year except for induction chemotherapy delivered (or to be delivered) prior to
the current course of radiation therapy
5. Female subjects of child-bearing potential must agree to use an adequate form of
contraceptive (e.g., hormonal, barrier method or abstinence) prior to study entry and
for the duration of the trial.
6. Are willing to refrain from using other treatments for oral mucositis until they
consult with the study investigator(s).
7. Are able to give written informed consent in a manner approved by the Institutional
Review Board and comply with the requirements of the study.
1. Have preexisting mucositis from other causes.
2. Are immunosuppressed or in chronic use of immunosuppressive drugs.
3. Have a known sensitivity to any of the constituents of the test product including
sensitivities to sandalwood oil, fragrances or any member of the Compositae family of
vascular plants (e.g., sunflowers, daisies, dahlias, etc.).
4. ECOG performance status > 3
5. Unwilling or unable to follow the protocol requirements.
6. Have any condition that in the opinion of the investigator would confound the
efficacy, safety and tolerability assessments, such as oral thrush.
7. Have participated in any clinical trial in the previous 30 days.
8. Are pregnant, breastfeeding, or unwilling to practice an acceptable form of birth
control during the study.